

## NTI to Present at the South-West Connect ASX Showcase

**Neurotech International Limited (ASX: NTI)** ("Neurotech" or "the Company") is pleased to advise that Chairman, Brian Leedman will be providing a company presentation at the inaugural Cannacord-Genuity South-West Connect ASX Showcase. Held in the picturesque South-West region of Western Australia at the Abbey Beach Resort | Broadwater Busselton, the conference will feature 38 in person ASX company presentations on 27 & 28 October 2021.

Mr Leedman will be presenting at midday WST on Day 2 of the conference to highlight the Company's recently completed pre-clinical studies using NTI164, a unique low THC cannabis strain for the treatment of MS and the expected completion and data analysis next month of the Phase I/II clinical study in children with ASD at Monash Children's Hospital in Melbourne. He will also sit on the Closing BDO Investment Panel. The Company presentation follows:

For those investors in Western Australia wanting to attend the event, register for FREE here:  
<https://www.southwestconnect.com.au>

The event is also being livestreamed live via Zoom.

Further details of the livestream and how to register (at no cost) can be found here:  
<https://www.southwestconnect.com.au/livestreamswconnect>

A recorded copy of the webinar will be made available following the event.

### Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

### Further Information

Brian Leedman  
Chairman  
[b.leedman@neurotechinternational.com](mailto:b.leedman@neurotechinternational.com)  
+61 (0)41 228 1780

Winton Willesee  
Non-Executive Director  
[winton@azc.com.au](mailto:winton@azc.com.au)  
+61 (0)41 066 7844

### Media:

Juliana Roadley  
IR Department  
[juliana.roadley@irdepartment.com.au](mailto:juliana.roadley@irdepartment.com.au)  
+61 (0)41 488 9863

### About Neurotech

Neurotech International Limited is a medical device and solutions company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of our proprietary NTI/Dolce cannabis strains. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mente Autism please visit <http://www.neurotechinternational.com>